Delve into the kinase inhibitors' diverse landscape, from cancer breakthroughs to autoimmune disease innovations.

Janus kinase (JAK) inhibitors are an important treatment option for people with chronic inflammatory diseases such as ...

In December 2024, the American Gastroenterological Association (AGA) published an updated clinical guideline for the ...

Dizal announces new findings on golidocitinib; to present clinical results at ELCC 2025 in Paris on March 26-29: Shanghai Saturday, March 22, 2025, 17:00 Hrs [IST] Dizal, a biopha ...

Dizal (SSE: 688192), a biopharmaceutical company committed to developing novel medicines for the treatment of cancer and ...

Janus kinase inhibitors (JAKis) are an important treatment option for people with chronic inflammatory diseases such as rheumatoid arthritis, psoriasis, Crohn's disease or ulcerative colitis.

Approval is for use in myelofibrosis patients with moderate to severe anaemia who are JAK-naive or previously treated with ...

Department of Medicine, University of Toronto, Women's College Hospital, and co-authors have found biologics targeting ...

Janus kinase inhibitors (JAKis ... Because these drugs specifically block cellular signalling pathways that are responsible for maintaining inflammatory responses, JAKi have been researched ...

Emory University's pioneering work with a class of small molecules known as JAK (janus kinase) inhibitors continues to show how HIV might be cured ...

Janus kinase (JAK) inhibitors have revolutionized ... of interleukin-7 and the thymic stromal lymphopoietin (TSLP) pathway, potentially bringing a novel approach to the control of AA, according ...